Safety, Tolerability and Pharmacokinetics of NCO-48 Fumarate in Healthy Subjects
Status:
Completed
Trial end date:
2020-10-13
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate the safety and tolerability of single oral doses of
NCO-48 Fumarate in healthy subjects. The secondary objectives are to evaluate the
pharmacokinetic (PK) profile of NCO-48 Fumarate and its active metabolite, tenofovir (TFV),
in healthy subjects following single oral doses and to evaluate the effect of food on the PK
of a 30 mg dose of NCO-48 Fumarate in healthy subjects.